Artiva Biotherapeutics (NASDAQ:ARTV) Director Ra Capital Management, L.P. Buys 24,944 Shares of Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Director Ra Capital Management, L.P. acquired 24,944 shares of the company’s stock in a transaction dated Friday, July 31st. The stock was acquired at an average cost of $9.93 per share, with a total value of $247,693.92. Following the purchase, the director owned 17,329,570 shares of the company’s stock, valued at approximately $172,082,630.10. This trade represents a 0.14% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Wednesday, July 29th, Ra Capital Management, L.P. bought 20,824 shares of Artiva Biotherapeutics stock. The shares were acquired at an average cost of $9.99 per share, for a total transaction of $208,031.76.
• On Friday, July 24th, Ra Capital Management, L.P. purchased 41,319 shares of Artiva Biotherapeutics stock. The stock was acquired at an average cost of $9.99 per share, for a total transaction of $412,776.81.
• On Thursday, July 23rd, Ra Capital Management, L.P. purchased 59,880 shares of Artiva Biotherapeutics stock. The stock was acquired at an average price of $9.96 per share, with a total value of $596,404.80.
• On Wednesday, July 22nd, Ra Capital Management, L.P. purchased 84,124 shares of Artiva Biotherapeutics stock. The stock was acquired at an average price of $9.93 per share, with a total value of $835,351.32.
• On Tuesday, July 21st, Ra Capital Management, L.P. acquired 120,582 shares of Artiva Biotherapeutics stock. The shares were bought at an average cost of $9.55 per share, with a total value of $1,151,558.10.
• On Friday, July 10th, Ra Capital Management, L.P. acquired 15,102 shares of Artiva Biotherapeutics stock. The shares were bought at an average price of $8.97 per share, for a total transaction of $135,464.94.
• On Monday, July 13th, Ra Capital Management, L.P. bought 6,552 shares of Artiva Biotherapeutics stock. The stock was bought at an average cost of $8.94 per share, for a total transaction of $58,574.88.
• On Friday, June 26th, Ra Capital Management, L.P. bought 1,876 shares of Artiva Biotherapeutics stock. The stock was bought at an average cost of $8.98 per share, for a total transaction of $16,846.48.
• On Thursday, June 25th, Ra Capital Management, L.P. bought 31,000 shares of Artiva Biotherapeutics stock. The shares were bought at an average price of $8.88 per share, with a total value of $275,280.00.
• On Tuesday, June 16th, Ra Capital Management, L.P. bought 124,893 shares of Artiva Biotherapeutics stock. The shares were bought at an average cost of $8.89 per share, with a total value of $1,110,298.77.

Artiva Biotherapeutics Stock Performance

Shares of NASDAQ ARTV opened at $10.10 on Friday. The company has a market cap of $249.67 million, a P/E ratio of -2.85 and a beta of 2.18. The firm’s fifty day moving average is $9.01 and its two-hundred day moving average is $7.51. Artiva Biotherapeutics, Inc. has a 52-week low of $2.22 and a 52-week high of $14.53.

Artiva Biotherapeutics (NASDAQ:ARTV) last announced its quarterly earnings results on Friday, May 8th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.07). As a group, analysts forecast that Artiva Biotherapeutics, Inc. will post -2.45 EPS for the current fiscal year.

Analyst Ratings Changes

ARTV has been the subject of a number of research reports. Wall Street Zen lowered Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, May 17th. Needham & Company LLC reaffirmed a “buy” rating and issued a $41.00 price objective on shares of Artiva Biotherapeutics in a research note on Monday, June 8th. Wedbush lifted their price objective on Artiva Biotherapeutics from $23.00 to $40.00 and gave the stock an “outperform” rating in a research note on Monday, May 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Artiva Biotherapeutics in a report on Tuesday, July 21st. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Artiva Biotherapeutics in a research report on Tuesday, May 26th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $39.00.

Institutional Trading of Artiva Biotherapeutics

Hedge funds have recently made changes to their positions in the business. Marshall Wace LLP bought a new position in shares of Artiva Biotherapeutics in the 2nd quarter valued at about $79,000. Qube Research & Technologies Ltd purchased a new stake in Artiva Biotherapeutics during the second quarter valued at approximately $58,000. Jane Street Group LLC purchased a new stake in Artiva Biotherapeutics during the second quarter valued at approximately $67,000. Bridgeway Capital Management LLC purchased a new stake in Artiva Biotherapeutics during the second quarter valued at approximately $53,000. Finally, BNP Paribas Financial Markets lifted its stake in shares of Artiva Biotherapeutics by 14,463.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company’s stock valued at $340,000 after purchasing an additional 117,733 shares during the last quarter.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.